pyrazinamide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
2328 98-96-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • pyrazinecarboxamide
  • pyrazinamide
  • 2-pyrazinecarboxamide
  • pyramizade
  • alpha-pyrazinamide
  • zinamide
A pyrazine that is used therapeutically as an antitubercular agent.
  • Molecular weight: 123.12
  • Formula: C5H5N3O
  • CLOGP: -0.68
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 1
  • TPSA: 68.87
  • ALOGS: -0.12
  • ROTB: 1
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
1.50 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 15 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 1.60 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 243.67 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 90 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 -0.634 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 0.573 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 55.847 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 4.753 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 86.240 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 90.140 % High 1
herg hERG pIC50 3.393 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 2.056 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 3.192 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 79.810 % High 1
kinase-safety-class ACVR2A,ACVR2B,AURKA,AXL,BRAF,CAMK2B,CAMK2D,CDK1,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,ERBB2,FLT3,GRK2,GRK3,IRAK1,ITK,JAK1,MAP3K21,MAPK7,MARK4,PDK2,PDK4,PIK3CD,PRKCD,PRKDC,SIK2,SIK3,STK33,TEK,ULK1 33
kinase-selectivity-class AXL,BRAF,CDK9,PRKDC 4
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 0.499 High 1
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 1.656 High 1
mh-clint Mouse hepatocyte intrinsic clearance 1.762 High 1
mppb Mouse plasma protein binding (% unbound) 93.520 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 1.054 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 85.190 % High 1
rat-kpuu-brain Rat brain Kpuu 2.547 % High 1
rh-clint Rat hepatocyte intrinsic clearance 0.532 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 97.380 % High 1
rppb Rat plasma protein binding (% unbound) 79.060 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 508.159 uM High 1

Approvals:

DateAgencyCompanyOrphan
June 3, 1971 FDA DAVA PHARMS INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms 1104.09 25.25 344 10820 42414 90574869
Paradoxical drug reaction 735.85 25.25 165 10999 5601 90611682
Drug resistance 415.43 25.25 152 11012 30297 90586986
Drug-induced liver injury 413.96 25.25 208 10956 90110 90527173
Acute hepatic failure 388.90 25.25 134 11030 22427 90594856
Immune reconstitution inflammatory syndrome 366.87 25.25 98 11066 6921 90610362
Immune reconstitution inflammatory syndrome associated tuberculosis 332.19 25.25 57 11107 446 90616837
Tuberculoma of central nervous system 292.92 25.25 49 11115 323 90616960
Hepatotoxicity 265.33 25.25 124 11040 45718 90571565
Drug interaction 220.44 25.25 217 10947 276236 90341047
Hepatitis 170.49 25.25 107 11057 70632 90546651
Tuberculosis 168.59 25.25 62 11102 12487 90604796
Pulmonary tuberculosis 163.40 25.25 48 11116 4786 90612497
Jaundice 160.82 25.25 79 11085 32438 90584845
Hepatic encephalopathy 131.23 25.25 53 11111 13719 90603564
Disseminated tuberculosis 130.39 25.25 37 11127 3262 90614021
Neuropathy peripheral 121.10 25.25 114 11050 136856 90480427
Hypertransaminasaemia 92.05 25.25 43 11121 15782 90601501
Eosinophilia 91.72 25.25 52 11112 28481 90588802
Pyrexia 85.14 25.25 224 10940 660261 89957022
Pancreatitis haemorrhagic 85.04 25.25 19 11145 630 90616653
Alanine aminotransferase increased 85.03 25.25 88 11076 118250 90499033
Aspartate aminotransferase increased 78.40 25.25 79 11085 102858 90514425
Meningitis tuberculous 73.97 25.25 17 11147 641 90616642
Lymphadenopathy 73.75 25.25 54 11110 45721 90571562
Electrocardiogram QT prolonged 71.14 25.25 64 11100 72392 90544891
Drug level decreased 67.84 25.25 30 11134 9700 90607583
Transaminases increased 64.76 25.25 46 11118 37146 90580137
Multiple organ dysfunction syndrome 60.55 25.25 57 11107 68279 90549004
Hepatocellular injury 57.90 25.25 39 11125 28919 90588364
Hepatitis toxic 55.97 25.25 20 11144 3705 90613578
Multiple-drug resistance 54.29 25.25 24 11140 7752 90609531
Rash maculo-papular 54.27 25.25 43 11121 40890 90576393
Hepatic function abnormal 53.74 25.25 45 11119 46243 90571040
Pain 52.29 25.25 29 11135 996312 89620971
Fatigue 51.91 25.25 40 11124 1153983 89463300
Distributive shock 50.00 25.25 18 11146 3406 90613877
Aspergillus infection 49.64 25.25 25 11139 10798 90606485
Hepatic failure 48.99 25.25 40 11124 39688 90577595
Anaemia 47.67 25.25 122 11042 352680 90264603
Hepatitis fulminant 47.52 25.25 18 11146 3927 90613356
Oedematous kidney 46.37 25.25 9 11155 147 90617136
Gamma-glutamyltransferase increased 46.35 25.25 38 11126 37914 90579369
Psychotic disorder 46.17 25.25 35 11129 31195 90586088
Fall 44.70 25.25 4 11160 481806 90135477
Hyperuricaemia 44.54 25.25 20 11144 6699 90610584
Optic neuropathy 42.49 25.25 15 11149 2683 90614600
Joint swelling 42.13 25.25 6 11158 503294 90113989
Toxic optic neuropathy 41.99 25.25 9 11155 245 90617038
Oedematous pancreatitis 41.18 25.25 11 11153 774 90616509
Immunosuppressant drug level decreased 41.15 25.25 12 11152 1164 90616119
Cholestatic liver injury 41.00 25.25 16 11148 3781 90613502
Lymph node tuberculosis 40.66 25.25 11 11153 812 90616471
Optic neuritis 40.45 25.25 21 11143 9657 90607626
Rash morbilliform 40.08 25.25 16 11148 4013 90613270
Respiratory failure 39.53 25.25 60 11104 118358 90498925
Hyperbilirubinaemia 38.42 25.25 23 11141 13913 90603370
Tuberculosis gastrointestinal 37.79 25.25 9 11155 397 90616886
Shock 37.65 25.25 30 11134 28748 90588535
Vomiting 37.09 25.25 193 10971 788100 89829183
Liver transplant 36.94 25.25 13 11151 2304 90614979
Hydrocephalus 36.80 25.25 17 11147 6077 90611206
Neurotoxicity 36.10 25.25 26 11138 21441 90595842
Swelling 35.05 25.25 5 11159 419053 90198230
Peritoneal tuberculosis 34.82 25.25 9 11155 557 90616726
Coagulopathy 34.20 25.25 26 11138 23263 90594020
Arthropathy 34.06 25.25 3 11161 366239 90251044
Hepatic necrosis 32.88 25.25 16 11148 6422 90610861
Exposure during pregnancy 32.73 25.25 83 11081 238327 90378956
Pathogen resistance 32.18 25.25 17 11147 8098 90609185
Peripheral swelling 32.15 25.25 6 11158 413100 90204183
Pulmonary toxicity 31.71 25.25 19 11145 11512 90605771
Sinusitis 31.40 25.25 3 11161 343085 90274198
Immune system disorder 31.15 25.25 19 11145 11886 90605397
Infection 31.03 25.25 4 11160 362090 90255193
Pain in extremity 30.22 25.25 9 11155 450520 90166763
Herbal toxicity 30.14 25.25 5 11159 31 90617252
Hepatosplenomegaly 30.11 25.25 12 11152 2997 90614286
Premature delivery 29.94 25.25 30 11134 38732 90578551
Synovitis 29.87 25.25 3 11161 329749 90287534
Polyneuropathy 29.30 25.25 22 11142 19319 90597964
Rheumatoid arthritis 28.79 25.25 5 11159 362609 90254674
Abdominal discomfort 27.83 25.25 12 11152 477316 90139967
Infectious pleural effusion 27.66 25.25 10 11154 1915 90615368
Granuloma 27.52 25.25 14 11150 6171 90611112
Jarisch-Herxheimer reaction 27.15 25.25 7 11157 429 90616854
Mastitis bacterial 26.97 25.25 5 11159 63 90617220
Generalised tonic-clonic seizure 26.93 25.25 27 11137 34876 90582407
Granulomatous lymphadenitis 26.09 25.25 6 11158 227 90617056
Visual acuity reduced 25.60 25.25 22 11142 23388 90593895
Abdominal lymphadenopathy 25.40 25.25 8 11156 1007 90616276

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Paradoxical drug reaction 1136.30 20.27 271 13483 4467 42603114
Immune reconstitution inflammatory syndrome 614.84 20.27 197 13557 9946 42597635
Drug-induced liver injury 537.63 20.27 257 13497 38016 42569565
Drug reaction with eosinophilia and systemic symptoms 502.69 20.27 253 13501 41822 42565759
Hepatotoxicity 365.28 20.27 173 13581 24994 42582587
Immune reconstitution inflammatory syndrome associated tuberculosis 333.12 20.27 68 13686 513 42607068
Drug resistance 287.55 20.27 163 13591 34085 42573496
Jaundice 233.49 20.27 143 13611 34446 42573135
Tuberculosis 215.52 20.27 91 13663 10008 42597573
Tuberculoma of central nervous system 169.12 20.27 34 13720 235 42607346
Hepatitis 159.40 20.27 103 13651 27197 42580384
Pulmonary tuberculosis 132.29 20.27 54 13700 5447 42602134
Drug interaction 118.93 20.27 264 13490 266735 42340846
Meningitis tuberculous 112.93 20.27 29 13725 650 42606931
Acute hepatic failure 111.06 20.27 69 13685 17004 42590577
Electrocardiogram QT prolonged 94.94 20.27 96 13658 47849 42559732
Disseminated tuberculosis 93.64 20.27 35 13719 2789 42604792
Immune system disorder 88.93 20.27 42 13712 6002 42601579
Tuberculosis of central nervous system 86.78 20.27 19 13735 207 42607374
Hydrocephalus 79.62 20.27 39 13715 6039 42601542
Lymphadenopathy 77.63 20.27 73 13681 33292 42574289
Drug level decreased 76.97 20.27 45 13709 9932 42597649
Multiple-drug resistance 67.20 20.27 37 13717 7285 42600296
Pyrexia 65.08 20.27 275 13479 393767 42213814
Neuropathy peripheral 62.14 20.27 115 13639 101738 42505843
Optic neuropathy 61.55 20.27 25 13729 2487 42605094
Granuloma 53.14 20.27 26 13728 4015 42603566
Optic neuritis 52.53 20.27 26 13728 4116 42603465
Lymph node tuberculosis 52.37 20.27 15 13739 512 42607069
Liver function test abnormal 51.92 20.27 58 13696 32333 42575248
Tubulointerstitial nephritis 51.45 20.27 57 13697 31491 42576090
Skin disorder 51.20 20.27 43 13711 16901 42590680
Hepatic failure 50.70 20.27 62 13692 38038 42569543
Alanine aminotransferase increased 49.19 20.27 96 13658 88310 42519271
Hepatitis fulminant 48.11 20.27 26 13728 4933 42602648
Eosinophilia 47.82 20.27 56 13698 32843 42574738
Mycobacterial infection 46.95 20.27 21 13733 2647 42604934
Hepatic enzyme increased 44.69 20.27 64 13690 45720 42561861
Diaphragmatic injury 44.34 20.27 10 13744 126 42607455
Granulomatous liver disease 43.95 20.27 14 13740 689 42606892
Pain 42.71 20.27 13 13741 244835 42362746
Hepatitis toxic 41.36 20.27 19 13735 2548 42605033
Tuberculosis of eye 40.21 20.27 8 13746 52 42607529
Unmasking of previously unidentified disease 39.90 20.27 15 13739 1214 42606367
Urinary tract inflammation 38.36 20.27 10 13744 238 42607343
Fall 38.20 20.27 14 13740 234506 42373075
Tuberculosis gastrointestinal 38.05 20.27 10 13744 246 42607335
Hyperuricaemia 37.22 20.27 28 13726 9396 42598185
Central nervous system vasculitis 37.07 20.27 12 13742 622 42606959
Pathogen resistance 36.55 20.27 30 13724 11420 42596161
Splenic embolism 36.51 20.27 10 13744 289 42607292
Oral candidiasis 36.36 20.27 33 13721 14372 42593209
Death 34.73 20.27 62 13692 471123 42136458
Toxic epidermal necrolysis 34.72 20.27 43 13711 26707 42580874
Sideroblastic anaemia 34.48 20.27 10 13744 357 42607224
Vitamin B1 decreased 33.96 20.27 10 13744 377 42607204
Transaminases increased 33.60 20.27 47 13707 32838 42574743
Encephalitis 33.51 20.27 26 13728 9132 42598449
Aspartate aminotransferase increased 32.69 20.27 75 13679 77088 42530493
Tuberculous pleurisy 32.65 20.27 10 13744 432 42607149
Condition aggravated 32.56 20.27 168 13586 260586 42346995
Mitochondrial neurogastrointestinal encephalopathy 32.26 20.27 5 13749 4 42607577
Bone tuberculosis 32.06 20.27 10 13744 459 42607122
Lymphopenia 31.82 20.27 37 13717 21526 42586055
Accelerated hypertension 31.80 20.27 9 13745 294 42607287
Deafness 31.02 20.27 29 13725 13111 42594470
Lichenoid keratosis 30.94 20.27 18 13736 3932 42603649
Thalamic infarction 30.15 20.27 11 13743 818 42606763
Product dose omission issue 29.14 20.27 7 13747 154358 42453223
Drug eruption 28.21 20.27 36 13718 23039 42584542
Mycobacterium abscessus infection 27.33 20.27 10 13744 750 42606831
Fatigue 27.24 20.27 63 13691 435578 42172003
Febrile neutropenia 27.14 20.27 13 13741 185690 42421891
Conductive deafness 27.06 20.27 9 13745 508 42607073
Splenomegaly 26.41 20.27 30 13724 17017 42590564
Psoas abscess 26.27 20.27 10 13744 837 42606744
Constipation 25.88 20.27 10 13744 162281 42445300
Brain oedema 25.75 20.27 29 13725 16298 42591283
Pulmonary granuloma 25.73 20.27 12 13742 1665 42605916
Atrial fibrillation 25.07 20.27 7 13747 139586 42467995
Rash maculo-papular 24.93 20.27 44 13710 37459 42570122
Blood bilirubin increased 24.84 20.27 47 13707 42205 42565376
Ototoxicity 24.84 20.27 13 13741 2312 42605269
Haemophagocytic lymphohistiocytosis 24.79 20.27 30 13724 18192 42589389
Immunosuppressant drug level decreased 24.77 20.27 12 13742 1812 42605769
Vomiting 24.16 20.27 168 13586 289555 42318026
Liver transplant rejection 23.89 20.27 13 13741 2500 42605081
Implant site infection 23.22 20.27 10 13744 1151 42606430
Jarisch-Herxheimer reaction 23.19 20.27 9 13745 794 42606787
Pulmonary sequestration 22.87 20.27 5 13749 54 42607527
Adrenocortical insufficiency acute 22.57 20.27 12 13742 2203 42605378
Malignant neoplasm progression 22.34 20.27 4 13750 108396 42499185
Hepatic encephalopathy 22.25 20.27 27 13727 16415 42591166
Marrow hyperplasia 22.23 20.27 10 13744 1277 42606304
Trisomy 21 22.20 20.27 8 13746 574 42607007
Renal atrophy 22.08 20.27 10 13744 1297 42606284
Tuberculoid leprosy 21.95 20.27 5 13749 66 42607515
Dilatation intrahepatic duct acquired 21.68 20.27 5 13749 70 42607511
Anaemia 21.32 20.27 159 13595 280119 42327462
Cachexia 21.30 20.27 19 13735 8085 42599496
HIV infection 20.86 20.27 10 13744 1475 42606106
Hepatic function abnormal 20.60 20.27 49 13705 51518 42556063

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Paradoxical drug reaction 1772.41 20.00 415 23942 9402 110555540
Drug reaction with eosinophilia and systemic symptoms 1515.76 20.00 597 23760 81498 110483444
Immune reconstitution inflammatory syndrome 981.37 20.00 288 24069 15938 110549004
Drug-induced liver injury 838.47 20.00 444 23913 119623 110445319
Immune reconstitution inflammatory syndrome associated tuberculosis 649.07 20.00 123 24234 931 110564011
Drug resistance 644.09 20.00 292 24065 56082 110508860
Hepatotoxicity 623.56 20.00 296 24061 63104 110501838
Acute hepatic failure 487.52 20.00 211 24146 36257 110528685
Tuberculoma of central nervous system 411.41 20.00 77 24280 540 110564402
Jaundice 406.97 20.00 217 24140 59019 110505923
Tuberculosis 350.79 20.00 136 24221 17638 110547304
Drug interaction 327.64 20.00 472 23885 499711 110065231
Pulmonary tuberculosis 284.97 20.00 98 24259 9041 110555901
Hepatitis 241.80 20.00 182 24175 89872 110475070
Neuropathy peripheral 210.24 20.00 227 24130 179050 110385892
Meningitis tuberculous 188.76 20.00 46 24311 1232 110563710
Disseminated tuberculosis 175.39 20.00 59 24298 5087 110559855
Electrocardiogram QT prolonged 162.25 20.00 157 24200 108803 110456139
Drug level decreased 150.37 20.00 76 24281 18472 110546470
Lymphadenopathy 149.45 20.00 119 24238 63716 110501226
Pyrexia 145.83 20.00 481 23876 897784 109667158
Hepatic encephalopathy 138.36 20.00 83 24274 28173 110536769
Eosinophilia 133.48 20.00 107 24250 57829 110507113
Alanine aminotransferase increased 129.48 20.00 180 24177 183593 110381349
Hydrocephalus 125.49 20.00 56 24301 10319 110554623
Immune system disorder 123.32 20.00 60 24297 13441 110551501
Optic neuropathy 111.27 20.00 41 24316 4617 110560325
Multiple-drug resistance 106.60 20.00 54 24303 13181 110551761
Aspartate aminotransferase increased 102.83 20.00 150 24207 159786 110405156
Hepatic failure 102.19 20.00 99 24258 68640 110496302
Pain 99.64 20.00 43 24314 954912 109610030
Lymph node tuberculosis 95.73 20.00 26 24331 1078 110563864
Tuberculosis of central nervous system 93.10 20.00 22 24335 515 110564427
Hepatitis toxic 91.47 20.00 38 24319 5883 110559059
Optic neuritis 88.38 20.00 45 24312 11102 110553840
Hepatitis fulminant 87.18 20.00 41 24316 8519 110556423
Transaminases increased 86.25 20.00 87 24270 63303 110501639
Hypertransaminasaemia 85.72 20.00 58 24299 24197 110540745
Fall 83.32 20.00 16 24341 603466 109961476
Pancreatitis haemorrhagic 74.61 20.00 21 24336 995 110563947
Hyperuricaemia 74.56 20.00 44 24313 14487 110550455
Rash maculo-papular 73.23 20.00 86 24271 74136 110490806
Granuloma 71.44 20.00 37 24320 9453 110555489
Tuberculosis gastrointestinal 70.12 20.00 18 24339 598 110564344
Fatigue 68.90 20.00 101 24256 1215857 109349085
Immunosuppressant drug level decreased 64.75 20.00 24 24333 2747 110562195
Hepatocellular injury 64.34 20.00 67 24290 50575 110514367
Anaemia 63.99 20.00 264 24093 546822 110018120
Hepatic function abnormal 63.62 20.00 88 24269 89207 110475735
Tubulointerstitial nephritis 60.49 20.00 67 24290 54217 110510725
Liver function test abnormal 58.45 20.00 74 24283 68876 110496066
Granulomatous liver disease 57.31 20.00 19 24338 1565 110563377
Pathogen resistance 57.12 20.00 40 24317 17632 110547310
Psychotic disorder 56.98 20.00 63 24294 50874 110514068
Hyperbilirubinaemia 56.88 20.00 50 24307 30621 110534321
Joint swelling 56.50 20.00 14 24343 442831 110122111
Mycobacterial infection 53.92 20.00 24 24333 4393 110560549
Sinusitis 53.18 20.00 3 24354 296685 110268257
Peripheral swelling 53.07 20.00 12 24345 404022 110160920
Peritoneal tuberculosis 51.65 20.00 14 24343 576 110564366
Sideroblastic anaemia 50.53 20.00 13 24344 436 110564506
Encephalitis 50.33 20.00 38 24319 18801 110546141
Liver transplant 49.89 20.00 23 24334 4566 110560376
Jarisch-Herxheimer reaction 49.70 20.00 16 24341 1201 110563741
Skin disorder 49.60 20.00 54 24303 42859 110522083
Rheumatoid arthritis 48.17 20.00 5 24352 299608 110265334
Diaphragmatic injury 48.14 20.00 10 24347 126 110564816
Liver transplant rejection 46.90 20.00 21 24336 3897 110561045
Vomiting 46.46 20.00 351 24006 910324 109654618
Arthropathy 45.70 20.00 5 24352 287517 110277425
Synovitis 45.58 20.00 4 24353 274088 110290854
Blood pressure increased 45.14 20.00 3 24354 258370 110306572
Central nervous system vasculitis 44.89 20.00 16 24341 1638 110563304
Wheezing 44.48 20.00 3 24354 255227 110309715
Adrenocortical insufficiency acute 44.39 20.00 21 24336 4419 110560523
Polyneuropathy 43.65 20.00 44 24313 31968 110532974
Product dose omission issue 43.38 20.00 9 24348 321773 110243169
Splenic embolism 43.08 20.00 10 24347 216 110564726
Unmasking of previously unidentified disease 42.93 20.00 18 24339 2850 110562092
Ototoxicity 42.72 20.00 20 24337 4111 110560831
Pain in extremity 41.80 20.00 28 24329 487090 110077852
Musculoskeletal stiffness 41.72 20.00 6 24351 279816 110285126
Splenomegaly 41.59 20.00 38 24319 24460 110540482
HIV infection 40.71 20.00 14 24343 1289 110563653
Toxic optic neuropathy 40.45 20.00 14 24343 1314 110563628
Lichenoid keratosis 40.19 20.00 22 24335 6280 110558662
Blood bilirubin increased 39.99 20.00 65 24292 75907 110489035
Stomatitis 39.81 20.00 6 24351 270236 110294706
Bone tuberculosis 39.79 20.00 12 24345 726 110564216
Tuberculosis of eye 39.59 20.00 8 24349 87 110564855
Hypertension 39.05 20.00 33 24324 510051 110054891
Haemophagocytic lymphohistiocytosis 38.74 20.00 41 24316 31518 110533424
Abdominal discomfort 37.49 20.00 20 24337 393838 110171104
Urinary tract inflammation 37.46 20.00 10 24347 388 110564554
Pancytopenia 37.14 20.00 116 24241 209497 110355445
Cholestatic liver injury 36.96 20.00 22 24335 7354 110557588
Febrile neutropenia 36.71 20.00 12 24345 316755 110248187
Cachexia 36.45 20.00 27 24330 12978 110551964
Oedematous kidney 36.24 20.00 9 24348 261 110564681
Weight increased 36.16 20.00 24 24333 419620 110145322
Toxic epidermal necrolysis 36.12 20.00 53 24304 56674 110508268
Distributive shock 35.97 20.00 20 24337 5884 110559058
Asthma 35.87 20.00 6 24351 250285 110314657
Antipsychotic drug level decreased 35.84 20.00 13 24344 1399 110563543
Constipation 35.81 20.00 17 24340 357769 110207173
Gamma-glutamyltransferase increased 35.78 20.00 55 24302 61254 110503688
Hepatic necrosis 35.71 20.00 24 24333 9898 110555044
Lymphopenia 35.45 20.00 44 24313 40126 110524816
Deafness 35.12 20.00 36 24321 26673 110538269
Conductive deafness 35.06 20.00 9 24348 299 110564643
Swelling 34.64 20.00 17 24340 351024 110213918
Haemolytic anaemia 34.64 20.00 32 24325 20888 110544054
Aspergillus infection 34.54 20.00 35 24322 25581 110539361
Condition aggravated 34.52 20.00 278 24079 734558 109830384
Brain oedema 33.98 20.00 38 24319 31060 110533882
Anxiety 33.62 20.00 17 24340 345061 110219881
Mycobacterium abscessus infection 33.45 20.00 13 24344 1693 110563249
Dry mouth 33.01 20.00 3 24354 199945 110364997
Rash morbilliform 32.93 20.00 21 24336 7930 110557012
Thalamic infarction 32.66 20.00 12 24345 1340 110563602
Contusion 32.55 20.00 6 24351 233355 110331587
Treatment noncompliance 32.53 20.00 58 24299 72932 110492010
Psoriatic arthropathy 32.36 20.00 3 24354 196758 110368184
Face oedema 31.71 20.00 38 24319 33431 110531511
Coagulopathy 31.68 20.00 42 24315 40869 110524073
Granulomatous lymphadenitis 31.54 20.00 9 24348 448 110564494
Mobility decreased 31.26 20.00 7 24350 237415 110327527
Discomfort 31.09 20.00 5 24352 214702 110350240
Mitochondrial neurogastrointestinal encephalopathy 30.99 20.00 5 24352 12 110564930
COVID-19 30.75 20.00 8 24349 245052 110319890
Accelerated hypertension 30.60 20.00 10 24347 787 110564155
Cutaneous tuberculosis 30.52 20.00 8 24349 289 110564653
Oedematous pancreatitis 30.30 20.00 12 24345 1642 110563300
Completed suicide 30.24 20.00 8 24349 242373 110322569
Hepatomegaly 30.23 20.00 30 24327 21384 110543558
Alopecia 29.91 20.00 22 24335 364731 110200211
Disseminated intravascular coagulation 29.86 20.00 41 24316 41245 110523697
Respiratory failure 29.21 20.00 109 24248 215223 110349719
Feeling abnormal 29.07 20.00 3 24354 180708 110384234
Vitamin B1 decreased 28.99 20.00 10 24347 929 110564013
Gastrooesophageal reflux disease 28.92 20.00 3 24354 179973 110384969
Injection site pain 28.51 20.00 3 24354 177919 110387023
Splenic abscess 28.38 20.00 10 24347 990 110563952
Injury 28.37 20.00 3 24354 177262 110387680
Psoas abscess 27.88 20.00 11 24346 1491 110563451
Contraindicated product administered 27.73 20.00 10 24347 248257 110316685
Generalised tonic-clonic seizure 27.71 20.00 46 24311 54634 110510308
Tuberculous pleurisy 27.68 20.00 9 24348 697 110564245
Pulmonary sequestration 27.68 20.00 5 24352 28 110564914
Back pain 27.17 20.00 25 24332 370971 110193971
Influenza 26.71 20.00 3 24354 169098 110395844
Dermatitis exfoliative 26.21 20.00 21 24336 11326 110553616
Product prescribing issue 26.07 20.00 22 24335 12750 110552192
Type 2 diabetes mellitus 25.95 20.00 4 24353 177228 110387714
Encephalopathy 25.90 20.00 56 24301 80999 110483943
Infection 25.83 20.00 25 24332 362175 110202767
Systemic lupus erythematosus 25.57 20.00 12 24345 254326 110310616
Headache 25.49 20.00 104 24253 882273 109682669
Hypersensitivity 25.36 20.00 31 24326 403967 110160975
Drug hypersensitivity 25.32 20.00 38 24319 454052 110110890
Pulmonary granuloma 25.26 20.00 12 24345 2549 110562393
Blood cholesterol increased 25.24 20.00 5 24352 184780 110380162
Muscle spasms 25.20 20.00 15 24342 278142 110286800
Diarrhoea 25.03 20.00 148 24209 1139357 109425585
Therapeutic product effect incomplete 25.02 20.00 9 24348 223796 110341146
Renal transplant failure 24.74 20.00 12 24345 2668 110562274
Oral candidiasis 24.51 20.00 39 24318 44721 110520221
Atrial fibrillation 24.40 20.00 10 24347 229632 110335310
Drug eruption 24.38 20.00 43 24314 53616 110511326
Ill-defined disorder 24.24 20.00 3 24354 156850 110408092
Lymph node abscess 24.07 20.00 5 24352 63 110564879
Mastitis bacterial 24.07 20.00 5 24352 63 110564879
Transplant rejection 23.45 20.00 28 24329 24539 110540403
Thrombocytopenia 23.38 20.00 144 24213 348741 110216201
Visual acuity reduced 23.34 20.00 32 24325 32141 110532801
Pancreatitis acute 23.23 20.00 45 24312 60229 110504713
Skin lesion 22.97 20.00 41 24316 51590 110513352
Ascites 22.96 20.00 58 24299 92750 110472192
Musculoskeletal pain 22.91 20.00 6 24351 183017 110381925
Oligohydramnios 22.89 20.00 13 24344 3981 110560961
Acid fast bacilli infection 22.86 20.00 6 24351 218 110564724
Marrow hyperplasia 22.70 20.00 10 24347 1786 110563156
Nicotinic acid deficiency 22.55 20.00 6 24351 230 110564712
Subacute hepatic failure 22.52 20.00 6 24351 231 110564711
Hereditary optic atrophy 22.51 20.00 5 24352 88 110564854
Multiple organ dysfunction syndrome 22.43 20.00 79 24278 151631 110413311
Therapeutic product effect decreased 22.38 20.00 13 24344 244303 110320639
Premature delivery 21.52 20.00 30 24327 30602 110534340
Tuberculoid leprosy 21.37 20.00 5 24352 112 110564830
Herbal toxicity 21.25 20.00 4 24353 29 110564913
Implant site infection 21.19 20.00 10 24347 2093 110562849
Chronic allograft nephropathy 21.08 20.00 10 24347 2116 110562826
Testicular mass 21.04 20.00 5 24352 120 110564822
Psoriasis 20.86 20.00 3 24354 139990 110424952
Acute respiratory distress syndrome 20.85 20.00 40 24317 53158 110511784
Hepatosplenomegaly 20.83 20.00 15 24342 6904 110558038
Drug intolerance 20.79 20.00 36 24321 406476 110158466
Overdose 20.63 20.00 13 24344 233781 110331161
Arachnoiditis 20.63 20.00 8 24349 1036 110563906
Stevens-Johnson syndrome 20.55 20.00 37 24320 46864 110518078
Death 20.39 20.00 82 24275 698787 109866155
Glomerulonephritis minimal lesion 20.28 20.00 8 24349 1083 110563859
Insomnia 20.26 20.00 30 24327 360560 110204382
Ocular icterus 20.26 20.00 14 24343 6039 110558903
Renal atrophy 20.15 20.00 10 24347 2336 110562606

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J04AK01 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIMYCOBACTERIALS
DRUGS FOR TREATMENT OF TUBERCULOSIS
Other drugs for treatment of tuberculosis
ATC J04AM05 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIMYCOBACTERIALS
DRUGS FOR TREATMENT OF TUBERCULOSIS
Combinations of drugs for treatment of tuberculosis
ATC J04AM06 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIMYCOBACTERIALS
DRUGS FOR TREATMENT OF TUBERCULOSIS
Combinations of drugs for treatment of tuberculosis
ATC J04AM09 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIMYCOBACTERIALS
DRUGS FOR TREATMENT OF TUBERCULOSIS
Combinations of drugs for treatment of tuberculosis
ATC J04AM10 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIMYCOBACTERIALS
DRUGS FOR TREATMENT OF TUBERCULOSIS
Combinations of drugs for treatment of tuberculosis
ATC J04AM11 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIMYCOBACTERIALS
DRUGS FOR TREATMENT OF TUBERCULOSIS
Combinations of drugs for treatment of tuberculosis
ATC J04AM12 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIMYCOBACTERIALS
DRUGS FOR TREATMENT OF TUBERCULOSIS
Combinations of drugs for treatment of tuberculosis
FDA EPC N0000175483 Antimycobacterial
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000995 Antitubercular Agents
CHEBI has role CHEBI:33231 antitubercular agent
CHEBI has role CHEBI:33281 antimicrobial agent
CHEBI has role CHEBI:50266 prodrug
CHEBI has role CHEBI:64946 anti-HIV agent

Related Drugs by ATC class:

J04AK Other drugs for treatment of tuberculosis 7 drugs
bedaquilinedelamanidethambutolmorinamidepretomanidterizidonethioacetazone
J04AM Combinations of drugs for treatment of tuberculosis 11 drugs
ethambutolisoniazidlevofloxacinlomefloxacinprotionamiderifabutinrifampicinstreptomycinsulfamethoxazolethioacetazonetrimethoprim

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Acute tuberculosis indication 25629007
Tuberculosis of meninges indication 58437007
Pulmonary tuberculosis indication 154283005 DOID:2957
Nutritional disorder contraindication 2492009 DOID:374
Alcoholism contraindication 7200002
Jaundice contraindication 18165001
Acute hepatitis contraindication 37871000
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Diabetes mellitus contraindication 73211009 DOID:9351
Gout contraindication 90560007 DOID:13189
Anemia due to enzyme deficiency contraindication 111577008
Acute hepatic failure contraindication 197270009
Disease of liver contraindication 235856003 DOID:409
Diabetic - poor control contraindication 268519009
Peripheral nerve disease contraindication 302226006
Porphyria contraindication 418470004
Diabetic peripheral neuropathy contraindication 424736006
Slow acetylator due to N-acetyltransferase enzyme variant contraindication 425079005
Chronic Hepatic Disease contraindication
Prolonged-Severe Nausea and Vomiting contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.39 acidic
pKa2 2.14 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Cytochrome P450 3A4 Enzyme IC50 6.89 WOMBAT-PK
Carbonic anhydrase 2 Enzyme IC50 5.77 WOMBAT-PK
Cytochrome P450 3A5 Enzyme IC50 4.89 WOMBAT-PK
3-oxoacyl-ACP synthase; Fatty acid synthase Fas; Probable fatty acid synthase Fas (Fatty acid synthetase) Enzyme INHIBITOR CHEMBL CHEMBL
Cyclopropane mycolic acid synthase 1 Enzyme WOMBAT-PK
Amidase; Nicotinamidase; Nicotinamidase/pyrazinamidase; Pyrazinamidase; Pyrazinamidase/nicotinamidase; Pyrazinamidase/nicotinamidase PncA Enzyme WOMBAT-PK

External reference:

IDSource
4017915 VUID
N0000146266 NUI
D00144 KEGG_DRUG
4017915 VANDF
C0034239 UMLSCUI
CHEBI:45285 CHEBI
PZA PDB_CHEM_ID
CHEMBL614 ChEMBL_ID
1046 PUBCHEM_CID
DB00339 DRUGBANK_ID
D011718 MESH_DESCRIPTOR_UI
786 INN_ID
7287 IUPHAR_LIGAND_ID
2KNI5N06TI UNII
8987 RXNORM
2368 MMSL
5390 MMSL
d00117 MMSL
002849 NDDF
13592004 SNOMEDCT_US
387076005 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
pyrazinamide HUMAN PRESCRIPTION DRUG LABEL 1 0054-0812 TABLET 500 mg ORAL ANDA 23 sections
PYRAZINAMIDE HUMAN PRESCRIPTION DRUG LABEL 1 10135-735 TABLET 500 mg ORAL ANDA 22 sections
PYRAZINAMIDE HUMAN PRESCRIPTION DRUG LABEL 1 10135-735 TABLET 500 mg ORAL ANDA 22 sections
Pyrazinamide Human Prescription Drug Label 1 33342-447 TABLET 500 mg ORAL ANDA 21 sections
Pyrazinamide HUMAN PRESCRIPTION DRUG LABEL 1 50090-0521 TABLET 500 mg ORAL ANDA 21 sections
Pyrazinamide HUMAN PRESCRIPTION DRUG LABEL 1 55695-026 TABLET 500 mg ORAL ANDA 22 sections
Pyrazinamide HUMAN PRESCRIPTION DRUG LABEL 1 60687-789 TABLET 500 mg ORAL ANDA 22 sections
Pyrazinamide HUMAN PRESCRIPTION DRUG LABEL 1 61748-012 TABLET 500 mg ORAL ANDA 22 sections
Pyrazinamide Human Prescription Drug Label 1 70954-484 TABLET 500 mg ORAL ANDA 21 sections